Needham analyst Serge Belanger maintained a Buy rating on Amphastar Pharmaceuticals today and set a price target of $34.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Serge Belanger has given his Buy rating due to a combination of factors including the recent FDA approval of Amphastar Pharmaceuticals’ AMP-015, a generic version of teriparatide. This approval is significant as it marks the company’s third product approval in 2025 and its first pen device combination product, which is expected to contribute positively to the company’s revenue.
Despite the competitive nature of the generic teriparatide market, the early launch of AMP-015 in the fourth quarter of 2025 is anticipated to help Amphastar maintain stable year-over-year sales. Furthermore, the company has projected promising growth for 2026, driven by other key products, which supports the optimistic outlook and the Buy rating provided by Belanger.
In another report released on December 9, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $30.00 price target.